Bailitienheng: Innovative drug BL-ARC002 approved for late-stage solid tumor clinical trials

Bailey Tianheng announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. Its independently developed Class I innovative drug BL-ARC002 injection has been approved to conduct clinical trials for the treatment of advanced solid tumors. This drug is a potential global first-class ARC drug with complete independent intellectual property rights, high target specificity, and tumor enrichment, and is expected to show good anti-drug resistance. The company reminded that the drug still needs to complete clinical trials and obtain approval before it can be marketed, and there are uncertainties in the research and development process.